BMI View: Despite growing in recent years, the absolute value of the Estonian pharmaceutical market
remains small and will continue to remain a marginal market in the Central and Eastern European region.
Low-cost generic drugs are prevalent in the market, with doctors obliged t ..."
BMI View: The Estonian State Agency for Medicines, Ravimiamet, has released pharmaceutical
consumption data for Q313. Figures show that sales of medicines rose year-over-year by 5% to EUR55mn
at wholesale prices, in line with our forecast for a slowdown in sales growt ..."
BMI View: Data for pharmaceutical sales in Q213 indicate that the market is experiencing a slowdown in
growth, which is in line with our forecasts for the full year. However, growth in Q213 compared to Q212
declined significantly, indicating that the relatively small ..."
BMI View: Strong Q113 results underpin our expectations for further growth in Estonia's pharmaceutical
sales in 2013. An improving macroeconomic picture, real wage growth and higher employment figures
point to a rise in state tax revenues. We therefore expect funding for health ..."
BMI View: On account of higher-than-expected pharmaceutical sales in 2012, we have revised upwards
our forecast for the market. Nevertheless, we remain of the opinion that the Estonian market will be of
modest interest at best to drugmakers, due to its small overall market valu ..."
Our outlook for the Estonian pharmaceutical market remains unchanged. While epidemiological trends will continue to stimulate the volume development of the market, patent expirations and government encouragement of the consumption of cheaper generic medicine will hamper value gro ..."
BMI View: We continue to view Estonia as a low-potential market, largely on account of its small - and
gradually declining - population. Short-term development of its pharmaceutical market will be shaped by
the factors including prevailing economic conditions, patent expiration ..."